Athira Pharma, Inc.

NasdaqGS:ATHA 주식 보고서

시가총액: US$101.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Athira Pharma 미래 성장

Future 기준 확인 0/6

Athira Pharma 의 수익은 연간 9% 감소할 것으로 예상되는 반면, 연간 수익은 54.2% 로 증가할 것으로 예상됩니다. 54.2% 연간. EPS는 연간 17.7% 만큼 성장할 것으로 예상됩니다.

주요 정보

-9.0%

수익 성장률

17.7%

EPS 성장률

Pharmaceuticals 수익 성장27.4%
매출 성장률54.2%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트20 Jun 2024

최근 미래 성장 업데이트

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

수익 및 매출 성장 예측

NasdaqGS:ATHA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20264-146-137-1173
12/31/2025N/A-127-133-1365
12/31/2024N/A-110-104-1276
3/31/2024N/A-116-100-100N/A
12/31/2023N/A-118-101-101N/A
9/30/2023N/A-121-90-90N/A
6/30/2023N/A-108-88-88N/A
3/31/2023N/A-102-83-82N/A
12/31/2022N/A-96-74-72N/A
9/30/2022N/A-82-77-75N/A
6/30/2022N/A-77-66-64N/A
3/31/2022N/A-67-54-52N/A
12/31/2021N/A-55-45-43N/A
9/30/2021N/A-46-38-36N/A
6/30/2021N/A-39-37-35N/A
3/31/2021N/A-27-33-30N/A
12/31/2020N/A-20-26-24N/A
9/30/2020N/A-13-15-14N/A
6/30/2020N/A-6-6-6N/A
3/31/2020N/A-6-4-4N/A
12/31/2019N/A-5-4-4N/A

애널리스트 미래 성장 예측

수입 대 저축률: ATHA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ATHA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ATHA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ATHA 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: ATHA 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ATHA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견